2.88 (-%)
As of Nov 08, 2024
Source:
Inhibikase Therapeutics, Inc is a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson’s disease (“PD”), Parkinson’s-related disorders and other diseases of the Abelson Tyrosine Kinases.
Country | United States |
Headquarters | atlanta, georgia |
Phone Number | ( 678 ) 392-3419 |
Industry | manufacturing |
CEO | Milton H. Werner |
Website | www.inhibikase.com |